Trial Profile
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary) ; Pegfilgrastim; Potassium iodide
- Indications Neuroblastoma; Phaeochromocytoma
- Focus Expanded access; Therapeutic Use
- 13 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 06 Oct 2020 Status changed from suspended to recruiting.
- 03 Apr 2020 Status changed from recruiting to suspended.